The objective of the long-term extension phase is to evaluate the long-term safety and tolerability of rufinamide as open-label adjunctive therapy, and possibly as monotherapy, kn patients with partial seizures. It will also allow patients continued access to rufinamide therapy.
Showing the most recent 10 out of 565 publications